1.
|
Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: seromprotocol, NCT00307606
|
|
2.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 1 to 50 Sponsor: Other Protocol IDs: HORCSCT-0902, NCT01015742
|
|
3.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 1 to 17 Sponsor: Other Protocol IDs: CDR0000686545, GPOH-COALL-08-09, EUDRACT-2009-012758-18, EU-21076, NCT01228331
|
|
4.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and under Sponsor: NCI Protocol IDs: COG-ANHL1131, ANHL1131, NCT01595048
|
|
5.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 and under at diagnosis Sponsor: NCI Protocol IDs: COG-AALL0631, AALL0631, NCT00557193
|
|
6.
|
Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: PETAL trial, EudraCT-Number 2006-001641-33, Krebshilfe Grant 107592, NCT00554164
|
|
7.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: CDR0000633503, GOELAMS-LH2007, GOELAMS-ID-RCB#2007-A01079-44, INCA-RECF0754, AMGEN-GOELAMS-LH2007, NCT00920153
|
|
8.
|
Phase: Phase III Type: Supportive care Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: 2327.00, NCI-2010-00323, P01CA018029, NCT00929695
|
|
9.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: JSPH-CLL-001, NCT01670812
|
|
10.
|
Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: PSCI-2003-232, NCT00084695
|
|
11.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 50 Sponsor: Other Protocol IDs: 06-254, NCT00476190
|
|
12.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: T1406, NCT00455286
|
|
13.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 month to 30 years Sponsor: NCI Protocol IDs: COG-AAML05P1, AAML05P1, NCT00553202
|
|
14.
|
Phase: Phase II Type: Treatment Status: Active Age: 8 to 55 Sponsor: NHLBI Protocol IDs: NHLBI-08-H-0046, 08-H-0046, NCT00608413
|
|
15.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000597508, P30CA023074, UARIZ-HSC-0567, HSC#0567, UARIZ-SRC17899, 05-0303-01, NCT00732498
|
|
16.
|
Phase: Phase II Type: Treatment Status: Active Age: 75 and under Sponsor: Other Protocol IDs: CDR0000600351, AMC-UUCM-2008-0038, 2008-0038, NCT00731328
|
|
17.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 60 Sponsor: NCI Protocol IDs: SWOG-S0805, S0805, NCT00792948
|
|
18.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 to 50 Sponsor: NCI Protocol IDs: OSU-08066, OSU 08066, 2008C0112, DFCI-06254, NCT01005758
|
|
19.
|
Phase: Phase II Type: Treatment Status: Active Age: 8 to 75 Sponsor: NHLBI Protocol IDs: 090087, 09-H-0087, NCT00859586
|
|
20.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 60 Sponsor: NCI, Other Protocol IDs: CDR0000642363, P30CA069533, OHSU-4913, ENZON-OHSU-4913, 4913, NCT01005914
|
|
21.
|
Phase: Phase II Type: Treatment Status: Active Age: 15 to 75 Sponsor: Other Protocol IDs: CDR0000659891, AMC-UUCM-2009-0579, 2009-0579, NCT01020734
|
|
22.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 to 65 Sponsor: Other Protocol IDs: CASE3Z07, NCI-2009-01319, NCT01093586
|
|
23.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 100429, NCT01191190
|
|
24.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: O-ESHAP-LH-2009, 2009-016026-13, NCT01195766
|
|
25.
|
Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: Allo-039, NCT01252784
|